Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity

Neurobiology of Disease

Volumn 79, Issue , 2015, Pages 150-163

  Ysselstein, Daniel ^a   Joshi, Mehul ^a   Mishra, Vartika ^a   Griggs, Amy M ^a   Asiago, Josephat M ^a   McCabe, George P ^b   Stanciu, Lia A ^c   Post, Carol Beth ^a   Rochet, Jean Christophe ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Aggregation; Familial mutation; Membrane; Neurodegeneration; Oligomer; Parkinson's disease; Phospholipid; Vesicle; Helix; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; MUTANT PROTEIN; ARTIFICIAL MEMBRANE; RECOMBINANT PROTEIN; SNCA PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; HYDROPHOBICITY; MEMBRANE BINDING; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHOSPHOLIPID BILAYER; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; RAT; WILD TYPE; ANIMAL; ARTIFICIAL MEMBRANE; CELL CULTURE; CELL SURVIVAL; ESCHERICHIA COLI; GENETICS; HUMAN; MESENCEPHALON; METABOLISM; MUTATION; NEURITE; PATHOLOGY; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DOPAMINERGIC NEURONS; ESCHERICHIA COLI; HUMANS; MEMBRANES, ARTIFICIAL; MESENCEPHALON; MUTATION; NEURITES; PROTEIN STRUCTURE, SECONDARY; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 84930203938     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.04.007     Document Type: Article

References (90)

1. Abedini A., Raleigh D.P. A role for helical intermediates in amyloid formation by natively unfolded polypeptides?. Phys. Biol. 2009, 6:15005.
2. Bartels T., et al. The N-terminus of the intrinsically disordered protein alpha-synuclein triggers membrane binding and helix folding. Biophys. J. 2010, 99:2116-2124.
3. Bertoncini C.W., et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1430-1435.
4. Bodner C.R., et al. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J. Mol. Biol. 2009, 390:775-790.
5. Bodner C.R., et al. Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry 2010, 49:862-871.
6. Burre J., et al. Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J. Neurosci. 2012, 32:15227-15242.
7. Burre J., et al. alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E4274-E4283.
8. Burre J., et al. Definition of a molecular pathway mediating alpha-synuclein neurotoxicity. J. Neurosci. 2015, 35:5221-5232.
9. Bussell R., Eliezer D. A structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 2003, 329:763-778.
10. Chandra S., et al. A broken α-helix in folded α-synuclein. J. Biol. Chem. 2003, 278:15313-15318.
11. Chartier-Harlin M.C., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
12. Comellas G., et al. Structural intermediates during alpha-synuclein fibrillogenesis on phospholipid vesicles. J. Am. Chem. Soc. 2012, 134:5090-5099.
13. Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
14. Cooper A.A., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
15. Davidson W.S., et al. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273:9443-9449.
16. Dedmon M.M., et al. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc. 2005, 127:476-477.
17. Delaglio F., et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6:277-293.
18. Dikiy I., Eliezer D. Folding and misfolding of alpha-synuclein on membranes. Biochim. Biophys. Acta 2012, 1818:1013-1018.
19. Drescher M., et al. Spin-label EPR on alpha-synuclein reveals differences in the membrane binding affinity of the two antiparallel helices. Chembiochem 2008, 9:2411-2416.
20. Ehrnhoefer D.E., et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 2008, 15:558-566.
21. Eliezer D., et al. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol. 2001, 307:1061-1073.
22. Fares M.B., et al. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet. 2014, 23:4491-4509.
23. Ferreon A.C., et al. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5645-5650.
24. Fonseca-Ornelas L., et al. Small molecule-mediated stabilization of vesicle-associated helical alpha-synuclein inhibits pathogenic misfolding and aggregation. Nat. Commun. 2014, 5:5857.
25. Fusco G., et al. Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. Nat. Commun. 2014, 5:3827.
26. Galvagnion C., et al. Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 2015, 11:229-234.
27. Georgieva E.R., et al. The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms. J. Biol. Chem. 2010, 285:28261-28274.
28. Giasson B.I., et al. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276:2380-2386.
29. Giehm L., et al. SDS-induced fibrillation of alpha-synuclein: an alternative fibrillation pathway. J. Mol. Biol. 2010, 401:115-133.
30. Gitler A.D., et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:145-150.
31. Greenbaum E.A., et al. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 2005, 280:7800-7807.
32. Grey M., et al. Acceleration of alpha-synuclein aggregation by exosomes. J. Biol. Chem. 2015, 290:2969-2982.
33. Haque F., et al. Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. J. Phys. Chem. B 2010, 114:4070-4081.
34. Jao C.C., et al. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8331-8336.
35. Jensen P.H., et al. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 1998, 273:26292-26294.
36. Jo E., et al. α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 2000, 275:34328-34334.
37. Jo E., et al. Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein. J. Mol. Biol. 2002, 315:799-807.
38. Jo E., et al. alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. Eur. J. Biochem. 2004, 271:3180-3189.
39. Kamp F., et al. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. Embo J. 2010, 29:3571-3589.
40. Karpinar D.P., et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. Embo J. 2009, 28:3256-3268.
41. Kiely A.P., et al. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 125:753-769.
42. Kruger R., et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
43. Lee H.-J., et al. Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 2002, 277:671-678.
44. Lee J.H., et al. Radiating amyloid fibril formation on the surface of lipid membranes through unit-assembly of oligomeric species of alpha-synuclein. PLoS ONE 2012, 7:e47580.
45. Lesage S., et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, 73:459-471.
46. Li J., et al. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 2001, 40:11604-11613.
47. Liu F., et al. Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. Free Radic. Biol. Med. 2008, 45:242-255.
48. Low P.A., et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014, 13:268-275.
49. Maltsev A.S., et al. Site-specific interaction between alpha-synuclein and membranes probed by NMR-observed methionine oxidation rates. J. Am. Chem. Soc. 2013, 135:2943-2946.
50. Marley J., et al. A method for efficient isotopic labeling of recombinant proteins. J. Biomol. NMR 2001, 20:71-75.
51. Masuda M., et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 2006, 45:6085-6094.
52. Mazumder P., et al. Insight into alpha-synuclein plasticity and misfolding from differential micelle binding. J. Phys. Chem. B 2013, 117:11448-11459.
53. Nakamura K., et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α-synuclein. J. Biol. Chem. 2011, 286:20710-20726.
54. Nasstrom T., et al. The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic. Biol. Med. 2011, 50:428-437.
55. Necula M., et al. Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. J. Biol. Chem. 2003, 278:46674-46680.
56. Ono K., Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem. 2006, 97:105-115.
57. Ouberai M.M., et al. alpha-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J. Biol. Chem. 2013, 288:20883-20895.
58. Pandey A.P., et al. Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. Biophys. J. 2009, 96:540-551.
59. Parihar M.S., et al. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int. J. Biochem. Cell Biol. 2009, 41:2015-2024.
60. Pasanen P., et al. A novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 2014, 35(2180):e1-e5.
61. Perrin R.J., et al. Interaction of human α-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 2000, 275:34393-34398.
62. Perrin R.J., et al. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J. Biol. Chem. 2001, 276:41958-41962.
63. Pfefferkorn C.M., et al. Depth of alpha-synuclein in a bilayer determined by fluorescence, neutron reflectometry, and computation. Biophys. J. 2012, 102:613-621.
64. Polymeropoulos M.H., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
65. Proukakis C., et al. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 2013, 80:1062-1064.
66. Qin Z., et al. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 2007, 282:5862-5870.
67. Reynolds N.P., et al. Mechanism of membrane interaction and disruption by alpha-synuclein. J. Am. Chem. Soc. 2011, 133:19366-19375.
68. Rochet J.C., et al. Molecular insights into Parkinson's disease. Prog. Mol. Biol. Transl. Sci. 2012, 107:125-188.
69. Rutherford N.J., et al. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J. Neurochem. 2014, 131:859-867.
70. Scholtz J.M., et al. Parameters of helix-coil transition theory for alanine-based peptides of varying chain lengths in water. Biopolymers 1991, 31:1463-1470.
71. Sharon R., et al. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003, 37:583-595.
72. Shulman J.M., et al. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 2011, 6:193-222.
73. Shvadchak V.V., et al. Specificity and kinetics of alpha-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe. J. Biol. Chem. 2011, 286:13023-13032.
74. Shvadchak V.V., et al. The mode of alpha-synuclein binding to membranes depends on lipid composition and lipid to protein ratio. FEBS Lett. 2011, 585:3513-3519.
75. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
76. Soper J.H., et al. Aggregation of alpha-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. J. Mol. Neurosci. 2011, 43:391-405.
77. Spillantini M.G., et al. α-Synuclein in Lewy bodies. Nature 1997, 388:839-840.
78. Strathearn K.E., et al. Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson's disease. Brain Res. 2014, 1555:60-77.
79. Takamori S., et al. Molecular anatomy of a trafficking organelle. Cell 2006, 127:831-846.
80. Trexler A., Rhoades E. Alpha-synuclein binds large unilamellar vesicles as an extended helix. Biochemistry 2009, 48:2304-2306.
81. Ulmer T.S., et al. Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 2005, 280:9595-9603.
82. Vamvaca K., et al. The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J. Mol. Biol. 2009, 389:413-424.
83. Venda L.L., et al. alpha-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010, 33:559-568.
84. Volles M.J., Lansbury P.T. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J. Mol. Biol. 2007, 366:1510-1522.
85. Wakabayashi K., et al. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 1998, 249:180-182.
86. Weinreb P.H., et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996, 35:13709-13715.
87. Winner B., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
88. Zakharov S.D., et al. Helical alpha-synuclein forms highly conductive ion channels. Biochemistry 2007, 46:14369-14379.
89. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
90. Zhang H., et al. In vitro study of alpha-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway. Biophys. J. 2013, 104:2706-2713.